ATE421535T1 - Peg-modifiziertes erythropoietin - Google Patents

Peg-modifiziertes erythropoietin

Info

Publication number
ATE421535T1
ATE421535T1 AT01970285T AT01970285T ATE421535T1 AT E421535 T1 ATE421535 T1 AT E421535T1 AT 01970285 T AT01970285 T AT 01970285T AT 01970285 T AT01970285 T AT 01970285T AT E421535 T1 ATE421535 T1 AT E421535T1
Authority
AT
Austria
Prior art keywords
peg
epo
conjugated
native
erythropoietin
Prior art date
Application number
AT01970285T
Other languages
English (en)
Inventor
Teruo Nakamura
Yasuo Sekimori
Minoru Machida
Hiromitsu Kawata
Hajime Miyamoto
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE421535T1 publication Critical patent/ATE421535T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT01970285T 2000-10-16 2001-09-28 Peg-modifiziertes erythropoietin ATE421535T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000315421 2000-10-16

Publications (1)

Publication Number Publication Date
ATE421535T1 true ATE421535T1 (de) 2009-02-15

Family

ID=18794529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01970285T ATE421535T1 (de) 2000-10-16 2001-09-28 Peg-modifiziertes erythropoietin

Country Status (8)

Country Link
US (2) US20040082765A1 (de)
EP (1) EP1333036B1 (de)
JP (1) JP5170931B2 (de)
AT (1) ATE421535T1 (de)
AU (1) AU2001290312A1 (de)
DE (1) DE60137525D1 (de)
ES (1) ES2320101T3 (de)
WO (1) WO2002032957A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
NZ541365A (en) 2002-12-27 2009-09-25 Diobex Inc Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1471153A3 (de) * 2003-03-21 2005-06-15 F. Hoffmann-La Roche Ag Transkriptionsaktivitätsassay
CA2458085A1 (en) 2003-03-21 2004-09-21 F. Hoffmann-La Roche Ag Transcriptional activity assay
WO2004108667A2 (en) * 2003-05-30 2004-12-16 Centocor, Inc. Formation of novel erythropoietin conjugates using transglutaminase
US9539337B2 (en) * 2003-12-10 2017-01-10 Nektar Therapeutics Compositions comprising two different populations of polymer-active agent conjugates
ES2346226T3 (es) * 2003-12-30 2010-10-13 Augustinus Bader Uso de la eritropoyetina para la regeneracion de tejido hepatico.
US7714114B2 (en) 2005-02-16 2010-05-11 Nektar Therapeutics Conjugates of an EPO moiety and a polymer
MX2007015819A (es) * 2005-06-13 2008-02-22 Nastech Pharm Co Suministro de derivados peptidicos a traves de la mucosa.
IL169377A (en) 2005-06-23 2012-09-24 Avigdor Shafferman Uniformly conjugated serine hydrolases
WO2007026772A1 (ja) * 2005-08-31 2007-03-08 Kaneka Corporation ネコ由来タンパク質のコード配列を含む外来性遺伝子を含むトランスジェニック鳥類およびその作製法
US20080171696A1 (en) * 2005-10-21 2008-07-17 Avigenics, Inc. Pharmacodynamically enhanced therapeutic proteins
CU23556A1 (es) 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
US7982010B2 (en) 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7985839B2 (en) 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
WO2007126808A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc Pegylated factor viii
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
CN103169984B (zh) 2006-07-25 2016-08-03 利普生技术有限公司 N末端聚唾液酸化
GB0615067D0 (en) * 2006-07-28 2006-09-06 Ttp Communications Ltd Reconfigurable signal processing scheme
CN101534847A (zh) * 2006-08-04 2009-09-16 普罗龙药品公司 修饰型促红细胞生成素
DK2101821T3 (da) 2006-12-15 2014-10-06 Baxter Healthcare Sa Faktor VIIA-(poly)sialinsyre-konjugat med forlænget halveringstid in vivo
US8110651B2 (en) 2008-01-11 2012-02-07 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en) * 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
EP2432489B1 (de) 2009-05-20 2016-10-05 BioMarin Pharmaceutical Inc. Varianten des natriuretischen peptids typ c
KR101773918B1 (ko) * 2009-09-15 2017-09-01 가부시키가이샤 가네카 수용성 장쇄 분자를 부가한 수식 에리스로포이에틴
WO2015130963A2 (en) 2014-02-27 2015-09-03 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
RU2768747C2 (ru) 2016-09-29 2022-03-24 Асцендис Фарма Гроус Дизордерс А/С Комбинаторная терапия с агонистами cnp контролируемого высвобождения

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5100664A (en) * 1985-09-20 1992-03-31 Cetus Corporation Human IL-2 as a vaccine adjuvant
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2502646B2 (ja) 1988-01-19 1996-05-29 松下電器産業株式会社 バ―ナ
JPH029900A (ja) * 1988-04-12 1990-01-12 Kirin Amgen Inc 修飾エリスロポエチン
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
NZ250375A (en) * 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
FI935485L (fi) * 1992-12-09 1994-06-10 Ortho Pharma Corp PEG-hydratsoni- ja PEG-oksiimisidoksen muodostavat reagenssit ja niiden proteiinijohdannaiset
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5977310A (en) * 1995-03-10 1999-11-02 Toshikazu Nakamura And Sumitomo Pharmaceuticals Co., Ltd. Peg-modified HGF
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
EP1731174A3 (de) * 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptide mit durch Hydrazon oder Oxim Gruppe kovalent gebunden N-terminalen Polyethylen-glycol
AU5773798A (en) * 1997-01-29 1998-08-18 Polymasc Pharmaceuticals Plc Pegylation process
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
JP2002531089A (ja) * 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー 赤血球産生性化合物
AU775937B2 (en) * 1999-01-14 2004-08-19 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2000044785A1 (en) 1999-01-29 2000-08-03 F. Hoffmann-La Roche Ag Gcsf conjugates
PE20010288A1 (es) * 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem

Also Published As

Publication number Publication date
US20060276634A1 (en) 2006-12-07
ES2320101T3 (es) 2009-05-19
JP5170931B2 (ja) 2013-03-27
EP1333036B1 (de) 2009-01-21
EP1333036A4 (de) 2004-09-29
AU2001290312A1 (en) 2002-04-29
WO2002032957A1 (en) 2002-04-25
JPWO2002032957A1 (ja) 2004-02-26
DE60137525D1 (de) 2009-03-12
US20040082765A1 (en) 2004-04-29
US8022191B2 (en) 2011-09-20
EP1333036A1 (de) 2003-08-06

Similar Documents

Publication Publication Date Title
DE60137525D1 (de) Peg-modifiziertes erythropoietin
DK1329458T5 (da) Peptider som sænker blodglucoseniveauer
ATE252601T1 (de) Lang wirkende insulinotrope peptide
DE69942231D1 (de) Ortspezifische duale pegylation von proteine
IS3824A (is) Protein með bundið polyethylen og aðferð til framleiðslu þess
DK1254237T3 (da) Aggregatfri uratoxidase til fremstilling af ikke-immunogene polymerkonjugater
ATE364654T1 (de) Polyamideketten von genauer länge und deren konjugate mit proteinen
DE3786000D1 (de) Conjugate dichter sterne.
EA200100838A1 (ru) Конъюгаты гксф
CY1110853T1 (el) Πεγκυλιωμενες ενωσεις glp-1
DE60321825D1 (de) Maleinsäureamid polymerderivate und ihre biokonjugate
DE69432141D1 (de) Taxane mit furyl-oder thienyl substituierten seitenketten
DE60236796D1 (de) Verzweigte polyalkylenglykole
DK0557199T3 (da) Polyethylenglycol-hirudin-konjugater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af tromboser
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
TR200200599T2 (tr) İnsan insülini monomerik analogları.
WO2004014951A3 (en) Binding molecules
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน
ITAR930014A1 (it) Snodo rotante per collane e bracciali tubolari

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1333036

Country of ref document: EP